Korecyte Bio Ltd. is a cell therapy startup based in London, the United Kingdom and was established in 2023-2024. Our mission is to develop next-generation cellular immunotherapies which can safely target a range of solid cancers and deliver improved outcomes for patients with cancer.
Ground-breaking modular platform technology ‘HypoxiCAR’
Our team has developed a ground-breaking modular platform technology ‘HypoxiCAR’. We are pioneering new approaches to genetically engineering a patient’s immune cells to identify and attack cancer.
Our unique approach enables these modified immune cells to lay dormant and circulate in the patient until they sense that they have entered a tumour where they awaken and start vigorously attacking the cancer.
Korecyte’s HypoxiCAR technology, which can be utilised within any CAR, preserves the killing potential of these cells, and significantly lowers the toxic side effects of these therapies to allow greater numbers of these cells to be given back to a patient. We understand the hardships that cancer patients, and their loved ones, face which is why we are committed to developing the next-generation CAR-T immunotherapy that is safe and effective for treating solid tumours. The HypoxiCAR technology is currently at the preclinical stage.
Learn more about Korecyte Bio
News & stories about Korecyte Bio
In our News section, you will find our most recent posts, annoucements, lists of events we will be attending and other useful information about Korecyte Bio. You can also find our most recent posts on social media such as Twitter and LinkedIn in our News section.
